| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ram R Miller | |
| Ayse L Mindikoglu | |||
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 | Q29620136 | ||
| Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. | Q33372766 | ||
| Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? | Q34537738 | ||
| Understudied populations with hepatitis C. | Q34984136 | ||
| Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. | Q35595775 | ||
| Chronic hepatitis C virus infection in older adults | Q36305517 | ||
| Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. The Collaborative Group | Q42628241 | ||
| Hepatitis C virus infection in the elderly | Q42978028 | ||
| Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa | Q42981515 | ||
| Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. | Q42983482 | ||
| Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea Study | Q42990661 | ||
| Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases | Q42994839 | ||
| Efficacy of interferon therapy in elderly patients with chronic hepatitis C. | Q42997762 | ||
| Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. | Q43034408 | ||
| The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. | Q43036906 | ||
| Interferon therapy for patients more than 60 years of age with chronic hepatitis C. | Q43037320 | ||
| Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. | Q43659671 | ||
| Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. | Q44010419 | ||
| Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan | Q44562902 | ||
| Clinical outcomes after transfusion-associated hepatitis C. | Q44746801 | ||
| Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study | Q44887145 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Treatment of Hepatitis C Virus in Elderly Persons With Interferon | Q45788483 | ||
| Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C. | Q50571426 | ||
| Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? | Q50576728 | ||
| Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. | Q50577281 | ||
| Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. | Q50580153 | ||
| Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. | Q53416462 | ||
| The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis | Q72089221 | ||
| Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients | Q79802314 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| epidemiology | Q133805 | ||
| P304 | page(s) | 128-34; quiz 124 | |
| P577 | publication date | 2008-12-12 | |
| P1433 | published in | Clinical Gastroenterology and Hepatology | Q5133759 |
| P1476 | title | Hepatitis C in the elderly: epidemiology, natural history, and treatment | |
| P478 | volume | 7 |
| Q56931621 | Q56931621 |
| Q36716281 | Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. |
| Q36690763 | Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis |
| Q35714925 | Hepatitis C virus and lichen planus: the real association. |
| Q61443480 | High prevalence of occult hepatitis C infection in predialysis patients |
| Q42780223 | Liver physiology and liver diseases in the elderly |
| Q37980037 | Viral hepatitis in the elderly |
Search more.